Technical Analysis for HCM - Hutchison China MediTech Limited

Grade Last Price % Change Price Change
grade C 23.87 1.14% 0.27
HCM closed up 1.14 percent on Tuesday, November 19, 2019, on approximately normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical HCM trend table...

Date Alert Name Type % Chg
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Overbought Stochastic Strength 1.14%
Overbought Stochastic Strength 2.53%
New Uptrend Bullish 4.51%
Volume Surge Other 4.51%
Overbought Stochastic Strength 4.51%
Stochastic Reached Overbought Strength 4.05%
Outside Day Range Expansion 4.05%
Overbought Stochastic Strength 4.05%

Older signals for HCM ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Hutchison China MediTech Limited engages in the research, development, manufacture, and sale of pharmaceuticals and health oriented consumer products primarily in the People's Republic of China. It operates through three segments: China Healthcare, Drug Research and Development, and Consumer Products. The company manufactures, distributes, and sells over-the-counter, prescription, and health supplements products under the Bai Yun Shan and Shang Yao brands; and offers drug research and development services. It also offers traditional Chinese medicine products in cardiovascular and cold/flu therapeutic areas. In addition, the company develops clinical drug candidates, including HMPL-004 that is in Phase III clinical trials for ulcerative colitis and Crohn's disease; Fruquintinib, which is in Phase III clinical trial for the treatment of colorectal, non-small cell lung, and gastric cancer; and Sulfatinib, a Phase 1b clinical trial product for neuroendocrine tumours, as well as Epitinib for treating non-small cell lung cancer. Further, it offers Theliatinib, a Phase I clinical trial product for the treatment of solid tumours; AZD6094 that is in Phase 1b clinical trial for treating non-small cell lung and gastric cancer; HMPL-523 and HMPL-689, which are preclinical stage products for the treatment of hematological cancers; and HMPL-453 that is in preclinical stage for the treatment of solid tumours. The company also offers organic and natural food, beverage, baby, and beauty care products; and distributes organic and natural products. Hutchison China MediTech Limited has strategic collaborations with multinational pharmaceutical and healthcare companies, including AstraZeneca AB (Publ); Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; and Nestlé Health Science SA. The company was founded in 2000 and is based in Hong Kong, Hong Kong. Hutchison China MediTech Limited operates as a subsidiary of Hutchison Healthcare Holdings Limited.
Health Healthcare Pharmaceutical Industry Beverage Pharmaceuticals Drug Discovery Clinical Trial Pharmaceutical Industry In China Non Small Cell Lung Cancer Ulcerative Colitis Design Of Experiments Beauty Care Products Clinical Trial Product Crohn's Disease Hematological Cancers Product Testing Preclinical Stage Products Treatment Of Hematological Cancers Gastric Cancer Medicine Products Nursing Research Traditional Chinese Medicine
Is HCM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 36.2
52 Week Low 16.47
Average Volume 159,984
200-Day Moving Average 24.2265
50-Day Moving Average 20.1234
20-Day Moving Average 21.3995
10-Day Moving Average 22.76
Average True Range 0.8551
ADX 30.83
+DI 35.0381
-DI 9.7159
Chandelier Exit (Long, 3 ATRs ) 21.5047
Chandelier Exit (Short, 3 ATRs ) 21.3953
Upper Bollinger Band 24.4797
Lower Bollinger Band 18.3193
Percent B (%b) 0.9
BandWidth 28.787588
MACD Line 1.0674
MACD Signal Line 0.808
MACD Histogram 0.2594
Fundamentals Value
Market Cap 2.9 Billion
Num Shares 121 Million
EPS 0.11
Price-to-Earnings (P/E) Ratio 217.00
Price-to-Sales 15.61
Price-to-Book 19.63
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 25.03
Resistance 3 (R3) 24.96 24.52 24.83
Resistance 2 (R2) 24.52 24.22 24.55 24.77
Resistance 1 (R1) 24.19 24.04 24.36 24.26 24.70
Pivot Point 23.75 23.75 23.83 23.78 23.75
Support 1 (S1) 23.42 23.45 23.59 23.49 23.04
Support 2 (S2) 22.98 23.27 23.01 22.97
Support 3 (S3) 22.65 22.98 22.91
Support 4 (S4) 22.72